Objective The Care-coordination Approach to Learning Lupus Self-Management (CALLS) study was designed to improve SLE disease self-management. This study aims to assess the benefits of the intervention ...

Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated ...

Lupus is a complex heterogeneous disease characterised by autoantibody production and immune complex deposition followed by damage to target tissues. Animal models of human diseases are an invaluable ...

Objective Many autoantibodies are known to be associated with SLE, although their role in clinical practice is limited because of low sensitivity and weak associations with clinical manifestations.

Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition of disease modification exists for SLE. We reviewed established ...

Objective To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE). Methods A phase ...

Correspondence to Dr Qianjin Lu, Department of Dermatology, Hunan Key Laboratory ofMedical Epigenomics, The Second Xiangya Hospital, Central South University,Changsha, Hunan 410011, China. ; ...

Objective To examine the efficacy and safety of telitacicept in the treatment of patients with SLE in everyday clinical practice. Methods Seventy-two patients with active SLE who received telitacicept ...

Background Recent guidelines for SLE recommend using a hydroxychloroquine (HCQ) dose less than 5.0 mg/kg/day to reduce the risk of retinopathy. To determine if this dose reduction would have an impact ...

4 Department of Preventive Medicine, Feinberg School of Medicine, Chicago, Illinois, USA Background/objective Patients with systemic lupus erythematosus (SLE) are at increased risk for adverse ...

Objective To generate comparative efficacy evidence of belimumab versus anifrolumab in SLE that can inform treatment practices. Methods The SLE Responder Index (SRI)-4 response at 52 weeks of ...

Objective Systemic lupus erythematosus (SLE) is a type of autoimmune disease that involves multiple organs involved as well as cytokine dysregulation. The treatment of SLE is still challenging due to ...